1Buyukkocak S,Ozturk HS, Tamer MN, et al.Erythocyte oxidant/arthoxidant status of drabetic patients[ J]. J Endocrinol Invest, 2000,23(4) :228-230.
2Bhatt DL,Topol EJ. Antiplatelet and anticoagulant therapy in the seconday prevention of ischemic heart disease[J]. Med Clin North Am,2000,84( 1 ) : 163-179.
3Gazis A,Page SR, Cockcroft JR. ACE inhibitors,diabetes and cardiovascular disease[ J] .Diabetologia, 1998,41(5) :595-597.
4Bidani AK, Schwarts M, Lewis E. Renal autoregulation and vulnerability to hypertensive ingury in remnant kidney[J]. Am J Physiol, 1997,252(6 Pt 2) :1003.
5Russ D, Pisani A, Ballerta MM, et al. Additive antiproteinurie effect of converting enzyme inhibitor and losatan in normotensive patients with IgA nephropathy[J] .Am J Kidney Dis, 1999,33(5):851-856.
6Hebert LA, Falkenheim ME, Nahman NS, et al. Combination ACE imhibtor and angiotensin Ⅱ receptor antagonist therapy in diabetic nephropathy[ J]. Am J Nephrol, 1999,19( 1 ) : 1-6.
7Duclos T W. Function of c-reactive protein [J]. Ann Med, 2000,32:274-278.
8Volanakis J E. Human c-reactive protein: expression,structure, and function [J]. Mol Immunol,2001,38:189-197.
9Ford E S. Body mass index, diabetes, and c-reactive protein among U S adults [J]. Diabetes Care,1999,22:1971-1977.
10Barzilay J I, Abraham L, Heckbert S R, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study[J]. Diabetes,2001,50:2384-2389.
